Skip to Main Content
Table I.

Specificity of Protection from EAE After Injection with Myelin-derived Sulfatide a


Treatment

MOG35-55/CFA/PT

Incidence
 (no. of mice [maximum score])

Mean maximum score

Mean day of onset
C57BL/6     
PBS 24/24
 [2(2), 7(3), 12(4), 3(5)] 3.7 12.9 
Sulfatide (d 0) 13/23b[10(0), 8(2), 1(3), 1(4)] 1.8 18 
Sulfatide (d − 7) 4/6
 [1(2), 3(3)] 1.9 15.4 
Sulfatide (d + 7) 2/6
 [2(2)] 0.7 16.1 
GM1 11/11
 [2(2), 5(3), 4(4)] 3.2 16 
Sphingomyelin 4/4
 [2(2), 2(4)] 3.0 13.3 
β-GalCer 6/6
 [1(2), 1(3), 2(4), 2(5)] 4.0 14.3 
Sulfatide − 0/5   
C57BL/6 – CD1dKO     
PBS 7/7
 [2(2), 2(3), 2(4), 1(5)] 2.9 13 
Sulfatide
 
+
 
8/8
 [1(2), 3(3), 3(4)]
 
3.0
 
12.8
 

Treatment

MOG35-55/CFA/PT

Incidence
 (no. of mice [maximum score])

Mean maximum score

Mean day of onset
C57BL/6     
PBS 24/24
 [2(2), 7(3), 12(4), 3(5)] 3.7 12.9 
Sulfatide (d 0) 13/23b[10(0), 8(2), 1(3), 1(4)] 1.8 18 
Sulfatide (d − 7) 4/6
 [1(2), 3(3)] 1.9 15.4 
Sulfatide (d + 7) 2/6
 [2(2)] 0.7 16.1 
GM1 11/11
 [2(2), 5(3), 4(4)] 3.2 16 
Sphingomyelin 4/4
 [2(2), 2(4)] 3.0 13.3 
β-GalCer 6/6
 [1(2), 1(3), 2(4), 2(5)] 4.0 14.3 
Sulfatide − 0/5   
C57BL/6 – CD1dKO     
PBS 7/7
 [2(2), 2(3), 2(4), 1(5)] 2.9 13 
Sulfatide
 
+
 
8/8
 [1(2), 3(3), 3(4)]
 
3.0
 
12.8
 
a

Groups of mice were injected i.p. with 20 μg of sulfatide, mono-GM1, sphingomyelin, β-GalCer, or PBS/vehicle only. On the same day (d 0), injected mice were immunized s.c. with MOG35-55/CFA/PT for the induction of EAE. Sulfatide was also injected either 7 d prior to (d − 7) or after (d + 7) the immunization with MOG35-55/CFA/PT. The incidence, mean maximum score, and mean day of onset of clinical EAE is shown.

b

P < 0.0001.

Close Modal

or Create an Account

Close Modal
Close Modal